66
Views
1
CrossRef citations to date
0
Altmetric
Original Research Article

Comparison of two strategies for the administration of injectable depot medroxyprogesterone acetate: among women who returned to a family planning clinic at three- or six-month intervals

, , , &
Pages 408-411 | Received 16 Mar 2016, Accepted 20 Jul 2016, Published online: 17 Aug 2016

References

  • O’Neil ME, Peipert JF, Zhao Q, et al. Twenty-four-month continuation of reversible contraception. Obstet Gynecol. 2013;122:1083–1091.
  • Susheela S, Sedgh G, Hussain R. Unintended pregnancy: worldwide levels, trends, and outcomes. Stud Fam Plann. 2010;41:241–250.
  • Blumenthal PD, Voedisch A, Gemzell-Danielsson K. Strategies to prevent unintended pregnancy: increasing use of long-acting reversible contraception. Hum Reprod Update. 2011;17:121–137.
  • Ferreira JM, Nunes FR, Modesto W, et al. Reasons for Brazilian women to switch from different contraceptives to long-acting reversible contraceptives. Contraception. 2014;89:17–21.
  • Trussell J. Contraceptive failure in the United States. Contraception. 2011;83:397–404.
  • Jain J, Jakimiuk AJ, Bode FR, et al. Contraceptive efficacy and safety of DMPA-SC. Contraception. 2004;70:269–275.
  • Fathizadeh N, Abdi F, Savabi M. A comparative study on satisfaction from hormonal contraceptives: depot medroxyprogesterone acetate (DMPA), Cyclofem and LD. Iran J Nurs Midwifery Res. 2011;16:304–308.
  • Modesto W, Bahamondes MV, Bahamondes L. Prevalence of low bone mass and osteoporosis in long-term users of the injectable contraceptive depot medroxyprogesterone acetate. J Womens Health (Larchmt). 2015;24:636–640.
  • Bahamondes L, Bottura BF, Bahamondes MV, et al. Estimated disability-adjusted life years averted by long-term provision of long acting contraceptive methods in a Brazilian clinic. Hum Reprod. 2014;29:2163–2170.
  • Beasley A, White KO, Cremers S, et al. Randomized clinical trial of self versus clinical administration of subcutaneous depot medroxyprogesterone acetate. Contraception. 2014;89:352–356.
  • Hubacher D, Goco N, Gonzalez B, et al. Factors affecting continuation rates of DMPA. Contraception. 1999;60:345–351.
  • Bahamondes L, Valeria Bahamondes M, Shulman LP. Non-contraceptive benefits of hormonal and intrauterine reversible contraceptive methods. Hum Reprod Update. 2015;21:640–651.
  • Castle WM, Sapire KE, Howard KA. Efficacy and acceptability of injectable medroxyprogesterone. A comparison of 3-monthly and 6-monthly regimens. S Afr Med J. 1978;53:842–845.
  • Ruminjo JK, Sekadde-Kigondu CB, Karanja JG, et al. Comparative acceptability of combined and progestin-only injectable contraceptives in Kenya. Contraception. 2005;72:138–145.
  • Bonny AE, Lange HLH, Made EM, et al. Serum adipocytokines and adipose weight gain: a pilot study in adolescent females initiating depot medroxyprogesterone acetate. Contraception. 2015;92:298–300.
  • Prabhakaran S, Sweet A. Self-administration of subcutaneous depot medroxyprogesterone acetate for contraception: feasibility and acceptability. Contraception. 2012;85:453–457.
  • Picardo C, Ferreri S. Pharmacist-administered subcutaneous depot medroxyprogesterone acetate: a pilot randomized controlled trial. Contraception. 2010;82:160–167.
  • Malarcher S, Meirik O, Lebetkin E, et al. Provision of DMPA by community health workers: what the evidence shows. Contraception. 2011;83:495–503.
  • Trussell J. Contraceptive efficacy. In: Hatcher RA, Trussell J, Nelson AL, et al. editors. Contraceptive technology: twentieth revised edition. New York: Ardent Media; 2011. p. 4–19.
  • Jacobstein R, Polis CB. Progestin-only contraception: injectables and implants. Best Pract Res Clin Obstet Gynaecol. 2014;28:795–806.
  • Westhoff C. Depot-medroxyprogesterone acetate injection (Depo-Provera): a highly effective contraceptive option with proven long-term safety. Contraception. 2003;68:75–87.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.